Phosphodiesterase-4 inhibition in COPD.
O'Byrne
Paul M
PM
Firestone Institute for Respiratory Health, and Department of Medicine, McMaster University Medical Center, Hamilton, ON L8N 3Z5, Canada. obyrnep@mcmaster.ca
Gauvreau
Gail
G
D000631:Aminopyridines / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4 / Q000502:physiology; D003521:Cyclopropanes / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D018579:Patient Selection; D058988:Phosphodiesterase 4 Inhibitors; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D012107:Research Design; D016896:Treatment Outcome
D000631:Aminopyridines; D001549:Benzamides; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D058988:Phosphodiesterase 4 Inhibitors; C424423:Roflumilast; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4